Hormone therapy and cardiovascular disease - still much to be learnt

    Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

    Sammanfattning

    Results from the recent randomized clinical trials indicating that hormone therapy (HT) does not provide cardiovascular protection, but potential harm, are in profound disagreement with the sound evidence from numerous observational and experimental studies. While the observational studies have mainly assessed symptomatic recently menopausal women, the randomized trials have studied symptomless elderly postmenopausal women with established coronary heart disease or various risk factors for cardiovascular disease. Thus, the recent trials have revealed only that HT does not provide secondary cardiovascular benefits. Since primary cardiovascular benefits of HT are rational but not yet proven in clinical trials, new studies are in demand. Until more data from recently menopausal symptomatic women are available, we need to base our decisions on existing evidence and good clinical practice. Although the potential of HT to provide cardiovascular benefits is decreased by advancing age and time since menopause, this should not preclude the use of individualized HT in younger postmenopausal women.
    Originalspråkengelska
    TidskriftGynecological Endocrinology
    Volym20
    Utgåva2
    Sidor (från-till)116-120
    Antal sidor5
    ISSN0951-3590
    DOI
    StatusPublicerad - 2005
    MoE-publikationstypA1 Tidskriftsartikel-refererad

    Vetenskapsgrenar

    • 312 Klinisk medicin

    Citera det här

    @article{df87eb69525a40c09a3fe14a362d4e01,
    title = "Hormone therapy and cardiovascular disease - still much to be learnt",
    abstract = "Results from the recent randomized clinical trials indicating that hormone therapy (HT) does not provide cardiovascular protection, but potential harm, are in profound disagreement with the sound evidence from numerous observational and experimental studies. While the observational studies have mainly assessed symptomatic recently menopausal women, the randomized trials have studied symptomless elderly postmenopausal women with established coronary heart disease or various risk factors for cardiovascular disease. Thus, the recent trials have revealed only that HT does not provide secondary cardiovascular benefits. Since primary cardiovascular benefits of HT are rational but not yet proven in clinical trials, new studies are in demand. Until more data from recently menopausal symptomatic women are available, we need to base our decisions on existing evidence and good clinical practice. Although the potential of HT to provide cardiovascular benefits is decreased by advancing age and time since menopause, this should not preclude the use of individualized HT in younger postmenopausal women.",
    keywords = "312 Clinical medicine, Obstetrics and gynecology",
    author = "Tomi Mikkola and Olavi Ylikorkala",
    year = "2005",
    doi = "10.1080/09513590400021235",
    language = "English",
    volume = "20",
    pages = "116--120",
    journal = "Gynecological Endocrinology",
    issn = "0951-3590",
    publisher = "Taylor & Francis",
    number = "2",

    }

    Hormone therapy and cardiovascular disease - still much to be learnt. / Mikkola, Tomi; Ylikorkala, Olavi.

    I: Gynecological Endocrinology, Vol. 20, Nr. 2, 2005, s. 116-120.

    Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review

    TY - JOUR

    T1 - Hormone therapy and cardiovascular disease - still much to be learnt

    AU - Mikkola, Tomi

    AU - Ylikorkala, Olavi

    PY - 2005

    Y1 - 2005

    N2 - Results from the recent randomized clinical trials indicating that hormone therapy (HT) does not provide cardiovascular protection, but potential harm, are in profound disagreement with the sound evidence from numerous observational and experimental studies. While the observational studies have mainly assessed symptomatic recently menopausal women, the randomized trials have studied symptomless elderly postmenopausal women with established coronary heart disease or various risk factors for cardiovascular disease. Thus, the recent trials have revealed only that HT does not provide secondary cardiovascular benefits. Since primary cardiovascular benefits of HT are rational but not yet proven in clinical trials, new studies are in demand. Until more data from recently menopausal symptomatic women are available, we need to base our decisions on existing evidence and good clinical practice. Although the potential of HT to provide cardiovascular benefits is decreased by advancing age and time since menopause, this should not preclude the use of individualized HT in younger postmenopausal women.

    AB - Results from the recent randomized clinical trials indicating that hormone therapy (HT) does not provide cardiovascular protection, but potential harm, are in profound disagreement with the sound evidence from numerous observational and experimental studies. While the observational studies have mainly assessed symptomatic recently menopausal women, the randomized trials have studied symptomless elderly postmenopausal women with established coronary heart disease or various risk factors for cardiovascular disease. Thus, the recent trials have revealed only that HT does not provide secondary cardiovascular benefits. Since primary cardiovascular benefits of HT are rational but not yet proven in clinical trials, new studies are in demand. Until more data from recently menopausal symptomatic women are available, we need to base our decisions on existing evidence and good clinical practice. Although the potential of HT to provide cardiovascular benefits is decreased by advancing age and time since menopause, this should not preclude the use of individualized HT in younger postmenopausal women.

    KW - 312 Clinical medicine

    KW - Obstetrics and gynecology

    U2 - 10.1080/09513590400021235

    DO - 10.1080/09513590400021235

    M3 - Article

    VL - 20

    SP - 116

    EP - 120

    JO - Gynecological Endocrinology

    JF - Gynecological Endocrinology

    SN - 0951-3590

    IS - 2

    ER -